Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: dr_lowenstein, DR Ryan, NASDAQ2020, IB_, namtae, Chasing
Search This Board: 
Last Post: 4/3/2020 1:07:15 PM - Followers: 889 - Board type: Free - Posts Today: 24

Elite Pharmaceuticals, Inc. (ELTP)


\Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite owns generic which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals Inc., USA.

Elite currently has eight commercial products currently being sold, six products filed with the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOx™.

Elite’s pipeline products include abuse-deterrent opioids utilizing the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse.


Located in Northvale, New Jersey, Elite operates a 55,000 square foot campus under Current Good Manufacturing Practice (“cGMP”) and is a United States Drug Enforcement Agency (“DEA”) registered facility for research, development, manufacturing and packaging of pharmaceutical products.
 

SEEKING ALPHA ARTICLE   Jan 01, 2020 
https://seekingalpha.com/article/4314697-breaking-out-of-chrysalis-elite-transformation?utm_medium=email&utm_source=seeking_alpha?app=1#alt2
 

About Elite's Abuse Deterrent Technology

Elite's abuse deterrent products utilize the Company's proprietary pharmacological abuse deterrent technology. Elite's abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.
\
 
Elite continues to expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

More information including Elite’s proprietary Abuse Resistant Technology can be found at http://www.elitepharma.com
 

Products & Pipeline
 
Screen%20Shot%202017-05-28%20at%2011.53.29%20AM.png
 
Elite’s principle product is SequestOx™,  an immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain. Additional products include bariatric, cardiovascular, antihistamine, skeletal muscle relaxants, antipsychotic, tricyclic antidepressant, along with a number of approved products pending manufacturing site transfer.
 
Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy's Laboratories and Valeant Pharmaceuticals International. Additional information regarding Elite’s wholly owned products, partnerships, and contract manufacturing can be found at  http://www.elitepharma.com/







\The list of pipeline products can be found at http://www.elitepharma.com/pipeline-generics
 
Leadership
 
Nasrat Hakim, Chairman, President & Chief Executive Officer
 
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership.  Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company. 

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
 

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: 
dianne@elitepharma.com

Corporate Headquarters
165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755


 

Miscellaneous Links:
 
Elite Pharmaceuticals News
http://ir.elitepharma.com/press_releases
 
SEC Filings
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov
https://www.clinicaltrials.gov/

https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
 
Yahoo Finance
https://finance.yahoo.com/quote/ELTP/?p=ELTP
 
Seeking Alpha
https://seekingalpha.com/symbol/ELTP

ELTP Daily Chart:
    


ELTP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP News: Current Report Filing (8-k) 02/10/2020 05:09:51 PM
ELTP News: Quarterly Report (10-q) 02/10/2020 04:15:36 PM
ELTP News: Current Report Filing (8-k) 12/12/2019 08:17:57 AM
ELTP News: Current Report Filing (8-k) 12/05/2019 05:12:54 PM
ELTP News: Current Report Filing (8-k) 11/19/2019 07:01:04 AM
PostSubject
#328254  Sticky Note Transcript link Q3 2020 Earnings Conference Call Chasing 02/11/20 02:04:28 PM
#327392  Sticky Note He's not selling the company until one ER aELmTPa 02/01/20 07:13:25 PM
#327387  Sticky Note (((((( Latest ELTP Seeking Alpha Article )))))) : NASDAQ2020 02/01/20 05:25:38 PM
#303967  Sticky Note Wishfull thinking , elite will need another 100 Dr_Thorfin 11/19/18 08:43:48 AM
#274770  Sticky Note memorable "calls" for elite pharma: dr_lowenstein 10/24/17 04:09:11 PM
#185967  Sticky Note The only topic here is ELTP. IH Dan (Retired) 02/23/16 09:32:46 PM
#330822   I hope Nas will implement a share buy mts 04/03/20 01:07:15 PM
#330821   The world meditation is coming up, shut sharkey1 04/03/20 12:53:30 PM
#330820   That came out wrong, editing, Elite does not sharkey1 04/03/20 12:14:00 PM
#330819   Sorry about the pop ups in this link, sharkey1 04/03/20 12:03:40 PM
#330818   One positive thing i just noticed is that jbdiver 04/03/20 11:56:46 AM
#330817   Dr Reddy hasn’t been a partner for a jour_trader 04/03/20 11:48:00 AM
#330816   They could be our BuyOut Candidate. NASDAQ2020 04/03/20 11:21:31 AM
#330815   Great post, no doubt factual and amusing at DSherman 04/03/20 11:17:30 AM
#330814   When are we going to get tylenol. tenor15824 04/03/20 11:14:58 AM
#330812   I remember hearing a load of hype about IB_ 04/03/20 11:07:15 AM
#330811   $94 Million antibiotic Imminent. NASDAQ2020 04/03/20 10:52:05 AM
#330810   tnx. I hope it is in the plans mistermudler 04/03/20 08:18:29 AM
#330809   I had emailed Dianne months ago and asked Gman24 04/03/20 08:10:48 AM
#330808   If you look above you'll see Glenmark is sharkey1 04/03/20 08:02:29 AM
#330807   can anyone update if Elite is targeting any mistermudler 04/03/20 07:41:08 AM
#330806   MESCAN, are you fine? Could you update the virelle 04/03/20 06:57:58 AM
#330805   Finally, Lannett posted pics of Elites Tabs sharkey1 04/03/20 06:04:45 AM
#330804   nah, sorry, just propaganda dr_lowenstein 04/03/20 01:19:49 AM
#330803   Nope!! Not Company Information Just Facts!! JustGoDeep 04/03/20 01:17:48 AM
#330802   dont bother, just company misinformation dr_lowenstein 04/03/20 01:10:49 AM
#330801   Read The plusonecoin Posts Above The Yellow Section JustGoDeep 04/03/20 01:06:01 AM
#330800   Recent Top 10 Pieces of BS Against ELTP YJ4LIFE 04/03/20 01:05:16 AM
#330799   Thanks to your reply. LIKED! YJ4LIFE 04/03/20 12:41:04 AM
#330798   my point is is as the antibio market keen_freakish 04/02/20 10:30:59 PM
#330797   what disinformation was posted ? LOL dr_lowenstein 04/02/20 10:18:13 PM
#330796   ELTP to the rescue...Shortage will be solved! YJ4LIFE 04/02/20 10:11:12 PM
#330795   Nothing to be sorry for, my post did DSherman 04/02/20 10:07:38 PM
#330794   What is your point? YJ4LIFE 04/02/20 10:07:25 PM
#330793   all the shorts will be covering their massive keen_freakish 04/02/20 10:04:57 PM
#330792   LOL LOL. I Believe the CEO more than YJ4LIFE 04/02/20 09:59:04 PM
#330791   one more thing.. all the people that pulled keen_freakish 04/02/20 09:56:48 PM
#330790   elite is not in the API business, sorry dr_lowenstein 04/02/20 09:55:03 PM
#330789   No doubt, monstrous net profits and excess cash DSherman 04/02/20 09:50:31 PM
#330787   Yup, ELTP Will Need To Produce A-LOT More JustGoDeep 04/02/20 09:41:35 PM
#330786   really? massive???? then what were those quantities????? got facts? dr_lowenstein 04/02/20 09:39:08 PM
#330785   Massive Launch Quantities NASDAQ2020 04/02/20 09:32:47 PM
#330784   easy to call a post BS, impossible to dr_lowenstein 04/02/20 09:16:19 PM
#330783   More to Come ! NASDAQ2020 04/02/20 09:04:50 PM
#330782   Easy!! Hold My Beer!! It Is Bullshit!! JustGoDeep 04/02/20 08:52:59 PM
#330781   So it is not only false but it dr_lowenstein 04/02/20 08:50:27 PM
#330780  Restored Nonsense, this is spelled out too clearly to DSherman 04/02/20 08:49:01 PM
#330779   WOW, thx for the step by step synopsis DSherman 04/02/20 08:45:51 PM
#330778   Agreed, the posts not only provide excellent data DSherman 04/02/20 08:41:49 PM
#330777   I believe THE Monster $1.3 billion market NASDAQ2020 04/02/20 08:39:42 PM
#330776   Absolutely spot on, Elite’s 12-20% of this market DSherman 04/02/20 08:38:43 PM
#330775   Now that’s some DD . NASDAQ2020 04/02/20 08:35:57 PM
#330774   BS is not information NASDAQ2020 04/02/20 08:33:52 PM
#330773   Hehehehehe, This Is Some GREAT ELTP Information!! JustGoDeep 04/02/20 07:11:42 PM
#330772   All that is FALSE and nonsense !!!!! dr_lowenstein 04/02/20 06:47:18 PM
#330771   plusonecoins Posts Above Explain A Lot-More About ELTP!! JustGoDeep 04/02/20 06:30:35 PM
PostSubject